Role of anterior vitreous, managing retinal folds in retinal detachment cases

Video
Conference|EURETINA

Dr Grazia Pertile discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.

Additional EURETINA coverage

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
A syringe and containers of liquid in front of the European Medicines Agency logo. Concept image for aflibercept Eylea EMA approval. Image credit: ©SoniaBonet – stock.adobe.com

Bayer submits EMA application for aflibercept 8mg third indication, retinal vein occlusion

Hattie Hayes
April 9th 2025
Article

In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular oedema

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A photo of the United States Food and Drug Administration FDA headquarters. Concept image for FDA ophthalmic presbyopia treatment application submission. Image credit: ©Tada Images – stock.adobe.com

Tenpoint Therapeutics submits US FDA New Drug Application for presbyopia treatment BRIMOCHOL PF

Jordana Joy
April 8th 2025
Article

Following Phase 3 pivotal trial BRIO-II, Tenpoint Therapeutics said they hope to launch BRIMOCHOL PF in 2026

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

An image of Plaza de Espana Square in Seville, Spain. Seville is home to the 2025 Congress on Controversies in Ophthalmology. Image credit: ©Anibal Trejo – stock.adobe.com

Surgical, medical and next-generation retina topics at COPHy

Hattie Hayes
April 4th 2025
Article

Retina topics serve as the backbone of the scientific programme at this year’s Congress on Controversies in Ophthalmology

A flip-calendar shows March 31st as the date, while the United States Food and Drug Administration and European Medicines Agency logos hover above. Image credit: ©Jenn Miranda, via Canva. FDA and EMA logos courtesy respective agencies.

Retina recap: EMA and US FDA approvals, March 2025

Sydney M Crago
April 3rd 2025
Article

Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space

© 2025 MJH Life Sciences

All rights reserved.